-
Anti-RPS6 antibody for signaling & ribosome studies
2026-08-12
Use the Anti-RPS6 (7B10) Mouse Monoclonal Antibody to connect growth signaling with protein synthesis, ribosome-associated biology, and phenotype in cultured cells or organoids. Its validated-use profile across Western blot, ICC/IF, and IP supports orthogonal workflows rather than relying on a single endpoint.
-
BI 2536 Workflow for PLK1-Driven Cancer Assays
2026-08-12
BI 2536 provides a selective way to connect PLK1 inhibition with mitotic arrest, growth suppression, and apoptosis in cancer models. This workflow separates reduced proliferation from true cell killing, improving interpretation of dose–response, cell-cycle, and tumor xenograft experiments.
-
Leucovorin Calcium: Methotrexate Rescue Research
2026-08-11
Leucovorin Calcium, also called calcium folinate, supplies reduced folate cofactors that can bypass methotrexate-related dihydrofolate reductase inhibition in research models. Product specifications support controlled aqueous preparation, cold storage, and prompt use of solutions in cell proliferation and cytotoxicity workflows.
-
RBMS1 Loss Enables Immunity in Triple-Negative Breast Cancer
2026-08-11
The reference study identifies the RNA-binding protein RBMS1 as an upstream regulator of PD-L1 stability in immune-cold triple-negative breast cancer. By destabilizing B4GALT1 mRNA, RBMS1 loss reduces PD-L1 glycosylation and promotes its ubiquitination and degradation, improving cytotoxic T-cell activity and the response to immune-based treatments.
-
Nelfinavir Mesylate in HIV and Ferroptosis Research
2026-08-10
Nelfinavir Mesylate supports two complementary research paths: quantitative HIV-1 protease inhibition assays and mechanistic studies of DDI2-NFE2L1 control during ferroptosis. This guide provides a practical workflow for stock preparation, concentration-response testing, pathway validation, and troubleshooting while separating established evidence from assay-development recommendations.
-
6-Thioguanine Blocks EV71 via BIRC3 Autophagy
2026-08-09
The 2025 BMC Microbiology study identifies 6-thioguanine as a potent in vitro inhibitor of EV71 replication and links its activity to suppression of BIRC3-mediated complete autophagy. Its strong selectivity in HT-29 cells supports further antiviral investigation, while the cell-based design and absence of clinical validation limit immediate therapeutic interpretation.
-
BEND Lipids Improve mRNA and CRISPR Delivery
2026-08-08
The reference study introduces branched endosomal disruptor lipids as an ionizable-lipid architecture that improves hepatic delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes, as well as T-cell transfection. Its structure–function analysis links terminal branching to enhanced endosomal penetration and disruption, offering a mechanistic direction for optimizing nonviral nucleic-acid delivery.
-
Oltipraz Workflow for Nrf2 and MASLD Research
2026-08-07
Oltipraz provides a defined small-molecule route to Nrf2-driven phase II enzyme induction, complementing integrated MASLD studies that measure autophagy and ferroptosis. This workflow shows how to connect GST and NQO1 outputs with lipid, inflammatory, and cell-death assays while controlling solubility, timing, and interpretation.
-
SIRT1-Regulated Ran Lactylation Drives Astrocyte Polarizatio
2026-08-07
This study reveals that lactate-mediated lactylation of Ran at lysine 123, regulated by SIRT1, is a crucial mechanism promoting astrocyte polarization following oxygen-glucose deprivation/reoxygenation injury. These findings advance understanding of non-histone lactylation in CNS repair and highlight new avenues for targeting metabolic-epigenetic pathways after spinal cord injury.
-
Ziprasidone HCl: Protocol-Driven Advances in Cancer and Neur
2026-08-06
Ziprasidone HCl is transforming experimental oncology and neuropharmacology by combining potent GOT1 inhibition with multimodal receptor antagonism. Discover how protocol refinements, advanced formulations, and troubleshooting tips unlock its full potential in translational research.
-
DiscoveryProbe Bioactive Compound Library Plus in Ligand Ass
2026-08-06
Leverage the DiscoveryProbe Bioactive Compound Library Plus to accelerate high-throughput ligand screening, pathway deconvolution, and drug discovery. This guide translates the latest biophysical assay innovations into actionable protocols, troubleshooting insights, and comparative advantages for cell-based and molecular research.
-
Haloprogin: Uncovering Antifungal Selectivity and Research I
2026-08-05
Explore the unique selectivity and research applications of Haloprogin, a broad-spectrum topical antimicrobial. This in-depth article reveals how its distinct antifungal and antibacterial profiles inform advanced microbiology workflows.
-
Ruthenium Red: Optimizing Ca2+ Transport Inhibition Workflow
2026-08-05
Ruthenium Red stands out as a high-affinity Ca2+ transport inhibitor, enabling precise control in calcium signaling and mechanotransduction research. This guide distills evidence-backed protocols, troubleshooting strategies, and advanced applications, drawing from recent breakthroughs in cytoskeleton-dependent autophagy and inflammation models.
-
Flexible 3D Nanocluster Arrays via Polymer Pen Lithography f
2026-08-04
This study introduces a reproducible approach for fabricating highly ordered 3D gold nanocluster arrays using polymer pen lithography, significantly advancing SERS substrate performance. The method enables flexible tuning of nanostructure architecture and achieves exceptional sensitivity and reproducibility, with important implications for biosensing and analytical chemistry.
-
PD-0332991 Enhances Cisplatin Response in NSCLC and Reverses
2026-08-04
The referenced study demonstrates that PD-0332991 (Palbociclib), a selective CDK4/6 inhibitor, can reverse cisplatin resistance in nonsmall cell lung cancer (NSCLC) models by enforcing G0/G1 cell cycle arrest and inhibiting Rb-E2F signaling. These findings offer a mechanistically grounded approach to overcoming chemotherapy resistance, with implications for improved NSCLC treatment regimens.